August 26th 2025
Where to find members of our editorial board at this year's European Society of Retina Specialists Congress
Risks and management of diabetic retinopathy in paediatric patients
January 13th 2021Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.
Roche’s DME candidate hits mark in 2 global Phase 3 studies
January 6th 2021Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.
AAO: Fingolimod for MS offers disease control with no development of uveitis
November 15th 2020Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
The importance of recognising Charles Bonnet syndrome in children
November 15th 2020A case series of 13 young patients with Charles Bonnet syndrome, which is characterised by visual hallucinations in individuals who are experiencing sight loss, showed that the patients all had inherited retinal diseases or congenital eye disorders but there was no link with visual dysfunction.
AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
November 15th 2020Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
AAO: Autologous retinal transplant for larger macular holes gaining traction
November 14th 2020Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.
AAO: Alcon virtual booth spotlights latest studies, retina product offerings
November 14th 2020Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.
COVID-19 presents opportunities for new directions in ophthalmology
November 13th 2020COVID-19 has had a significant impact on the entire global community. As we look to the future to advance the provision of eyecare excellence, opportunities for innovation must be embraced and new, patient-centric ways of managing clinical practices adopted.
Maintaining quality and safety in retina clinics during a pandemic
October 7th 2020To maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimise clinic visits and maximise use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximising safety and patients’ vision outcomes.
Considering the presence of retinal fluid when treating nAMD patients
August 20th 2020Recent international ophthalmic congresses have featured advocates for and against the need for complete fluid resolution when treating nAMD, with some ophthalmologists arguing for a zero-tolerance approach to the presence of fluid, and others claiming some residual fluid can be tolerated and may be helpful in some patients.